Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma.

Trial Profile

Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2015

At a glance

  • Drugs Amrubicin (Primary) ; Carboplatin (Primary)
  • Indications Malignant thymoma; Thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 15 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top